ES2440393R1 - Un método para aumentar el efecto de una forma activada potenciada de un anticuerpo - Google Patents

Un método para aumentar el efecto de una forma activada potenciada de un anticuerpo Download PDF

Info

Publication number
ES2440393R1
ES2440393R1 ES201390006A ES201390006A ES2440393R1 ES 2440393 R1 ES2440393 R1 ES 2440393R1 ES 201390006 A ES201390006 A ES 201390006A ES 201390006 A ES201390006 A ES 201390006A ES 2440393 R1 ES2440393 R1 ES 2440393R1
Authority
ES
Spain
Prior art keywords
activated form
antibody
effect
antibody against
increasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES201390006A
Other languages
English (en)
Other versions
ES2440393A2 (es
Inventor
Oleg Iliich Epshtein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2010129291/15A external-priority patent/RU2525156C2/ru
Priority claimed from RU2010129294/15A external-priority patent/RU2542414C2/ru
Priority claimed from RU2010129298/15A external-priority patent/RU2526153C2/ru
Priority claimed from RU2010129295/15A external-priority patent/RU2531049C2/ru
Priority claimed from RU2010129292/15A external-priority patent/RU2523557C2/ru
Priority claimed from RU2010129290/15A external-priority patent/RU2525155C2/ru
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2010130353/15A external-priority patent/RU2542445C2/ru
Priority claimed from RU2010130355/15A external-priority patent/RU2530638C2/ru
Priority claimed from RU2010130356/15A external-priority patent/RU2542453C2/ru
Priority claimed from RU2010130358/15A external-priority patent/RU2519695C2/ru
Priority claimed from RU2011110106/15A external-priority patent/RU2523451C2/ru
Priority claimed from RU2011127058/15A external-priority patent/RU2536232C2/ru
Priority claimed from RU2011127053/15A external-priority patent/RU2565400C2/ru
Priority claimed from RU2011127055/15A external-priority patent/RU2536230C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Priority claimed from RU2011127052/15A external-priority patent/RU2503462C2/ru
Priority claimed from RU2011127059/15A external-priority patent/RU2536234C2/ru
Application filed by Individual filed Critical Individual
Publication of ES2440393A2 publication Critical patent/ES2440393A2/es
Publication of ES2440393R1 publication Critical patent/ES2440393R1/es
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies

Abstract

Un método para aumentar el efecto de una forma activada potenciada de un anticuerpo. La presente invención proporciona un método para aumentar el efecto de una forma activada potenciada de un anticuerpo contra una molécula biológica endógena que se selecciona del grupo de la proteína S-100, el antígeno prostático específico, el receptor de la insulina y el receptor de la angiotensina II, mediante la combinación de una forma activada potenciada de un anticuerpo contra dicha molécula biológica endógena, con una forma activada potenciada de un anticuerpo contra la NO sintasa endotelial. La presente invención proporciona también una composición farmacéutica que comprende a) una forma activada potenciada de un anticuerpo contra una molécula biológica endógena que se selecciona del grupo de la proteína S-100, el antígeno prostático específico, el receptor de la insulina y el receptor de la angiotensina II, y b) una forma activada potenciada de un anticuerpo contra la NO sintasa endotelial.
ES201390006A 2010-07-15 2011-07-15 Un método para aumentar el efecto de una forma activada potenciada de un anticuerpo Pending ES2440393R1 (es)

Applications Claiming Priority (37)

Application Number Priority Date Filing Date Title
RU2010129295/15A RU2531049C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы
RU2010129298 2010-07-15
RU2010129292 2010-07-15
RU2010129292/15A RU2523557C2 (ru) 2010-07-15 2010-07-15 Способ лечения вегетососудистой дистонии и фармацевтическая композиция для лечения вегетососудистой дистонии
RU2010129291 2010-07-15
RU2010129290/15A RU2525155C2 (ru) 2010-07-15 2010-07-15 Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для комплексной терапии хронической сердечной недостаточности
RU2010129294 2010-07-15
RU2010129291/15A RU2525156C2 (ru) 2010-07-15 2010-07-15 Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии
RU2010129298/15A RU2526153C2 (ru) 2010-07-15 2010-07-15 Способ повышения фармакологической активности действующего вещества лекарственного средства и фармацевтическая композиция
RU2010129290 2010-07-15
RU2010129295 2010-07-15
RU2010129294/15A RU2542414C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций
RU2010130353 2010-07-21
RU2010130355/15A RU2530638C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения органических заболеваний нервной системы, психоорганического синдрома и энцефалопатий различного генеза
RU2010130348 2010-07-21
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2010130356 2010-07-21
RU2010130358/15A RU2519695C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания
RU2010130353/15A RU2542445C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2010130356/15A RU2542453C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство и способ лечения вегето-сосудистой дистонии, синдрома головокружения различного генеза и кинетозов
RU2010130355 2010-07-21
RU2010130358 2010-07-21
RU2011110106 2011-03-17
RU2011110106/15A RU2523451C2 (ru) 2011-03-17 2011-03-17 Способ лечения хронической сердечной недостаточности и фармацевтическая композиция для лечения хронической сердечной недостаточности
RU2011127053/15A RU2565400C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения заболеваний мочеполовой системы и способ лечения заболеваний мочеполовой системы
RU2011127055 2011-07-01
RU2011127058/15A RU2536232C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения болезни альцгеймера и способ лечения болезни альцгеймера
RU2011127052 2011-07-01
RU2011127055/15A RU2536230C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения неврологическо-поведенческих рассторойств развития и способ лечения неврологическо-поведенческих расстройств развития
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127052/15A RU2503462C2 (ru) 2011-07-01 2011-07-01 Способ лечения головокружения различного генеза, кинетозов и вегето-сосудистой дистонии (варианты) и лекарственное средство
RU2011127053 2011-07-01
RU2011127059 2011-07-01
RU2011127059/15A RU2536234C2 (ru) 2011-07-01 2011-07-01 Нейротропное лекарственное средство и способ лечения органических заболеваний нервной системы, психоорганического синдрома и энцефалопатий различного генеза
RU2011127051 2011-07-01
RU2011127058 2011-07-01
PCT/IB2011/002350 WO2012007845A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody

Publications (2)

Publication Number Publication Date
ES2440393A2 ES2440393A2 (es) 2014-01-28
ES2440393R1 true ES2440393R1 (es) 2014-10-10

Family

ID=44863151

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201390006A Pending ES2440393R1 (es) 2010-07-15 2011-07-15 Un método para aumentar el efecto de una forma activada potenciada de un anticuerpo

Country Status (25)

Country Link
US (3) US9308275B2 (es)
EP (1) EP2593140A2 (es)
JP (2) JP2013538186A (es)
KR (1) KR20140014059A (es)
AR (1) AR082247A1 (es)
AU (1) AU2011278038B2 (es)
BR (1) BR112013000840A2 (es)
CA (1) CA2804966A1 (es)
CZ (1) CZ2013105A3 (es)
DE (1) DE112011102358T5 (es)
DK (1) DK201370079A (es)
EA (1) EA030566B1 (es)
EE (1) EE201300006A (es)
ES (1) ES2440393R1 (es)
FI (1) FI20135143L (es)
FR (1) FR2962656A1 (es)
GB (1) GB2495884B (es)
IT (1) ITTO20110639A1 (es)
LT (1) LT5988B (es)
MX (1) MX2013000543A (es)
NO (1) NO20130222A1 (es)
NZ (1) NZ606767A (es)
PE (1) PE20130398A1 (es)
SG (2) SG10201505561TA (es)
WO (1) WO2012007845A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064860A1 (en) * 2010-07-15 2013-03-14 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of theating genitourinary system disorders
US9308275B2 (en) * 2010-07-15 2016-04-12 Oleg Iliich Epshtein Method of increasing the effect of an activated-potentiated form of an antibody
AU2011281248B2 (en) * 2010-07-21 2017-02-02 Oleg Lliich Epshtein Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
SG187578A1 (en) * 2010-07-21 2013-03-28 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
EP2450375A1 (en) 2010-11-09 2012-05-09 Sandoz Gmbh Cell culture medium and process for protein expression, said medium and process comprising a PAM inhibitor
RU2013111962A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1466622A1 (en) * 2001-12-26 2004-10-13 Oleg Iliich Epshtein Medicinal agent and method for curing diseases accompanied with vascular dystonia
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP1547611A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3134718A (en) 1963-12-12 1964-05-26 Schering Corp Pregna-1,4-dienes and compositions containing same
US3901967A (en) 1973-09-10 1975-08-26 Union Corp Sustained release of atropine
SE393532B (sv) 1974-05-02 1977-05-16 Draco Ab Sett att framstella en farmaceutisk zinkberedning for astadkommande av en smaklig, fordragbar, peroral zinklosning innehallande ett zinkkomplex
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
SU1331508A1 (ru) 1985-08-14 1987-08-23 Киевский Кабельный Завод "Укркабель" Устройство дл пневматического массажа урогенитальной сферы человека
FI101344B1 (fi) 1988-03-31 1998-06-15 Tanabe Seiyaku Co Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
US4987127A (en) 1989-01-31 1991-01-22 Dal Sirany Method of treating a virus outbreak
SU1730144A1 (ru) 1989-02-24 1992-04-30 Научный Центр По Разработке И Внедрению Современных Методов Молекулярной Диагностики Способ подавлени репродукции вирусов
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
RU2007989C1 (ru) 1991-11-12 1994-02-28 Акционерное общество "Трейдис" Способ габович подбора гомеопатических препаратов и их разовой дозы
EP0663836B1 (en) 1992-10-08 1997-07-09 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
DK140992D0 (da) 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5879677A (en) 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
RU2033784C1 (ru) 1993-05-28 1995-04-30 Индивидуальное частное предприятие "Диалог" Устройство для репродуцирования гомеопатических и изопатических препаратов
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
WO1995026325A2 (en) 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US5629286A (en) 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
IL110035A0 (en) 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
RU2137483C1 (ru) 1995-08-02 1999-09-20 Божедомов Владимир Александрович Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
WO1997009056A1 (fr) 1995-09-07 1997-03-13 L'oreal Extrait d'iridacees et compositions le contenant
KR19990082461A (ko) 1996-02-12 1999-11-25 올레그 일리치 엡슈타인 약제 및 생물체를 약제로 치료하는 방법
IL118096A0 (en) 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
RU2104032C1 (ru) 1997-03-11 1998-02-10 Общество с ограниченной ответственностью "Снежный барс" Способ усиления лечебного эффекта лекарственных средств
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
DE19746868A1 (de) 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
RU2122858C1 (ru) 1997-12-29 1998-12-10 Яковлева Людмила Борисовна Гомеопатическое лекарственное средство седативного действия "вернисон"
US6326360B1 (en) 1998-03-11 2001-12-04 Grelan Pharmaceuticals Co., Ltd. Bubbling enteric coated preparations
RU2187334C2 (ru) 1998-05-22 2002-08-20 Эпштейн Олег Ильич Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2144370C1 (ru) 1999-01-06 2000-01-20 Титиева Наталья Михайловна Гомеопатическое лекарственное средство для лечения гипертрофии предстательной железы
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2177795C1 (ru) 2001-02-15 2002-01-10 Эпштей Олег Ильич Гомеопатическое лекарственное средство для лечения и профилактики аденовирусных инфекций у детей
RU2192882C1 (ru) 2001-04-18 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
RU2199345C1 (ru) 2001-12-26 2003-02-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции углеводного и жирового обмена
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76640C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation
RU2253478C1 (ru) 2003-10-01 2005-06-10 Эпштейн Олег Ильич Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества
JP2007518692A (ja) * 2004-01-20 2007-07-12 アステラス製薬株式会社 勃起不全治療方法
BRPI0514903A (pt) * 2004-09-03 2008-06-24 Hansens Lab proteìnas vegetais ou leite fermentado compreendendo ligando de receptor e uso dos mesmos
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
MX2008012549A (es) * 2006-04-04 2009-01-14 Dong A Pharm Co Ltd Agente para la prevencion y tratamiento de hiperplasia prostatica que comprende compuesto de pirazolopirimidinona.
RU2438707C2 (ru) 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
EP2040756A4 (en) * 2006-07-13 2013-01-09 Mazence Inc COMPOSITION CONTAINING ACIDIC AMINO ACID CHELATE AND METAL ACCELERATING METAL ABSORPTION
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
US20130189707A1 (en) 2010-01-26 2013-07-25 Svetlana Alexandrovna Sergeeva Method of determination of autoantibody level by means of enzyme immunoassay
US9308275B2 (en) * 2010-07-15 2016-04-12 Oleg Iliich Epshtein Method of increasing the effect of an activated-potentiated form of an antibody
US20130064860A1 (en) * 2010-07-15 2013-03-14 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of theating genitourinary system disorders
CA2804964C (en) 2010-07-15 2016-06-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
EA029436B1 (ru) 2010-07-15 2018-03-30 Олег Ильич ЭПШТЕЙН Комбинированная фармацевтическая композиция для лечения рассеянного склероза и инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями, и способы лечения указанных заболеваний
AU2011278040B2 (en) 2010-07-15 2016-06-02 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
EP2593482A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
AU2011281248B2 (en) * 2010-07-21 2017-02-02 Oleg Lliich Epshtein Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
WO2012014078A2 (en) * 2010-07-21 2012-02-02 Olge Iliich Epshtein Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
EP2596019A2 (en) * 2010-07-21 2013-05-29 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
AU2011281247B2 (en) 2010-07-21 2015-07-30 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
SG187578A1 (en) * 2010-07-21 2013-03-28 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
CN103119060A (zh) * 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗阿尔兹海默病的方法
RU2535033C2 (ru) 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
US20120263725A1 (en) 2010-08-06 2012-10-18 Epshtein Oleg Iiiich Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
RU2517084C2 (ru) 2010-08-06 2014-05-27 Олег Ильич Эпштейн Способ и средство для ингибирования продукции или усиления элиминации белка р24
SG187732A1 (en) 2010-08-06 2013-03-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
RU2535034C2 (ru) 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
US20130171161A1 (en) 2010-12-23 2013-07-04 Oleg Iliich Epshtein Method and composition for the treatment of diseases caused by or associated with hiv
JP5418549B2 (ja) * 2011-07-06 2014-02-19 アイシン精機株式会社 車両のドアアウタハンドル装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome
EP1466622A1 (en) * 2001-12-26 2004-10-13 Oleg Iliich Epshtein Medicinal agent and method for curing diseases accompanied with vascular dystonia
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP1547611A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Jonas W. B. et al. A critical overview of homeopathy. Ann. Intern. Med. 2003, Vol. 138, páginas 393-399 (todo el documento) *
Markel A. L. et al . Hypotensive activity of ultralow doses of antibodies to factors involved in the regulation of vascular tone. Bulletin of Experimental Biology and Medicine. Supplement 1, 2003 (todo el documento) *
Shang A. et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. The Lancet. 27.08.2005, Vol. 366, páginas 726-732 (todo el documento) *
Vickers A. J. et al. Clinical Trials of Homeopathy and Placebo: Analysis of a Scientific Debate. The Journal of Alternative and Complementary Medicine. 2000, Vol. 6, Nº 1, páginas 49-56 (todo el documento) *

Also Published As

Publication number Publication date
CA2804966A1 (en) 2012-01-19
ES2440393A2 (es) 2014-01-28
AU2011278038B2 (en) 2017-02-02
EA030566B1 (ru) 2018-08-31
WO2012007845A3 (en) 2012-03-29
US9308275B2 (en) 2016-04-12
BR112013000840A2 (pt) 2016-06-07
US20160244531A1 (en) 2016-08-25
SG187038A1 (en) 2013-02-28
US20140079696A1 (en) 2014-03-20
EA201300126A1 (ru) 2013-12-30
FI20135143L (fi) 2013-02-15
US20160251448A1 (en) 2016-09-01
DE112011102358T5 (de) 2013-04-25
DK201370079A (en) 2013-02-14
LT5988B (lt) 2014-01-27
EP2593140A2 (en) 2013-05-22
GB2495884B (en) 2017-05-31
FR2962656A1 (fr) 2012-01-20
AU2011278038A1 (en) 2013-03-07
CZ2013105A3 (cs) 2013-05-22
AR082247A1 (es) 2012-11-21
GB201302649D0 (en) 2013-04-03
SG10201505561TA (en) 2015-08-28
GB2495884A (en) 2013-04-24
PE20130398A1 (es) 2013-04-10
KR20140014059A (ko) 2014-02-05
ITTO20110639A1 (it) 2012-01-16
NO20130222A1 (no) 2013-03-22
MX2013000543A (es) 2013-10-28
EE201300006A (et) 2013-08-15
WO2012007845A2 (en) 2012-01-19
LT2013016A (lt) 2013-11-25
JP2013538186A (ja) 2013-10-10
NZ606767A (en) 2015-08-28
JP2016216483A (ja) 2016-12-22

Similar Documents

Publication Publication Date Title
ES2440393R1 (es) Un método para aumentar el efecto de una forma activada potenciada de un anticuerpo
CL2014003370A1 (es) Composición acuosa estable de anticuerpos anti-baffr; y dispositivo de suministro de la composición.
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
CR20120371A (es) Antagonistas de pcsk9
CL2015000431A1 (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
MA34091B1 (fr) Anticorps anti-cd40
CY1116488T1 (el) Αντισωματα anti-προπερδινης
CO7250445A2 (es) Proteínas de unión a antígeno st2
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
CL2014001123A1 (es) Anticuerpos anti-il 36r; composicion farmaceutica que lo contiene; polinucleotido aislado que codifica el anticuerpo; metodo para la produccion del anticuerpo; kit de diagnostico que lo contiene.
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
CL2013003123A1 (es) Molécula de nucleasa híbrida; composición que comprende dicha molécula; método para preparar dicha molécula; método para tratar lupus eritematoso sistémico.
BR112013023653A2 (pt) anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
CL2012003094A1 (es) Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.
CL2013001089A1 (es) Anticuerpos que se une especificamente a tnfalfa humano; composicion farmacéutica que la comprende; molécula de ácido nucleico aislado; vector; metodo para reducir la tendencia a la agregación de un anticuerpo.
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
PE20160528A1 (es) Anticuerpos
GB2496342A (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 20170828